Stanley Capital Mergers and Acquisitions Summary

Private Equity Firm Profile

In the last 3 years, Stanley Capital has acquired 2 companies.

Stanley Capital’s most common sector for investment islife science (100%). The Firm’s most common investment types include divestiture (50%) and secondary buyout (50%). In total, Stanley Capital has invested in 2 different countries. Its largest (disclosed) acquisition occurred in 2020 when it acquired Noden Pharma DAC for $53M.

Join Mergr to view Stanley Capital’s full profile and discover more small private equity firms just like it.

M&A Summary

  • M&A Total Activity2
    • M&A Buy Activity2
  • Total Sectors Invested 1
  • Total Countries Invested 2
  • M&A Buy/Sell Connections 1

Stanley Capital is a private equity partnership that pursues healthcare and technology investments. The Firm targets businesses valued from $250 million to $2.5 billion with defensible business models and opportunities for growth. Stanley Capital was formed in 2019 and is headquartered in London.


Investment Criteria

Sectors of Interest: Healthcare Services, Information Technology

Target Transaction Types: Buyout (LBO, MBO, MBI), Divestiture

Geographic Preferences: United Kingdom

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value 250 2,500
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '17 '18 '19 '20 '21 '22 T
Buy (0.4/yr) # - - - 1 - 1 2
vol $53M $53M
Sell (0.0/yr) # - - - - - - 0
  2

Most Recent M&A

Company Date Value Type
Laboratoire X.O 2022-10-04 - Secondary Buyout
Saint-Cloud, France · www.laboratoirexo.com
Noden Pharma DAC 2020-09-09 53M USD Divestiture
Dublin, Ireland · www.nodenpharma.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 2 (100%) 53M (100%) 2 (100%) 53M (100%)
Total 2 $53M 2 $53M

Acquisitions By Geo

State/Country Current # Value All-time # Value
Ireland 1 (50%) 53M (100%) 1 (50%) 53M (100%)
France 1 (50%) - 1 (50%) -
Total 2 $53M 2 $53M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Divestiture 1 (50%) 53M (100%) 1 (50%) 53M (100%)
Secondary Buyout 1 (50%) - 1 (50%) -
Total 2 $53M 2 $53M

Deal Values

buy # Total
< $100M 1 $53M
TOTAL $53M
Largest Noden Pharma DAC
$53M (2020-09-09)

M&A Connections

Deals
Acquired from
Investor(s)
50%
1 (50%)
Strategic(s)
50%
1 (50%)

Investor Summary

Investor Type

Private Equity Firm

Size

Small

Established

2019

Specialist/Generalist

Generalist

Leadership

James Brooks

Team Member

Patrick Hargutt

Team Member

Simon Cottle

Team Member

 Subscribe to unlock this and 185,414
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.4K Private Equity Firms
  • 176K M&A Transactions
  • 181K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.5K M&A Advisors
    (Investment Banks and Law Firms)
  • 66K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal